Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Tumors With FGFR Mutations or Fusions (MATCH Subprotocol K2)
NCT06351371Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erdafitinib in malignant solid neoplasm, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Jul 2018; status: active, not recruiting.
02
Drugs
erdafitinib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06351371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351371.